Phase 2 study of talabostat and cisplatin in stage IV melanoma.

被引：0
|
作者：
Uprichard, MJ
O'Day, SJ
Pavlick, AC
Richards, DA
Frenette, G
Stephenson, J
Anthony, S
Pacciucci, PA
Vrhovac, V
Cunningham, C
机构：
[1] Point Therapeut, Boston, MA USA
[2] Inst Canc Res, Med Grp, Los Angeles, CA USA
[3] NYU, Kaplan Canc Ctr, New York, NY 10016 USA
[4] Tyler Canc Ctr, Tyler, TX USA
[5] Carolinas Med Ctr, Charlotte, NC USA
[6] Canc Ctr Carolinas, Greenville, SC USA
[7] Canc Ctr NW, Spokane, WA USA
[8] Mary Crowley Med Res Ctr, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：725S / 725S
页数：1
相关论文
共 50 条
  • [1] Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma.
    Cunningham, C.
    Pavlick, A. C.
    Khan, K. D.
    Frenette, G.
    O'Day, S.
    Stephenson, J.
    Gonzalez, R.
    Yang, Z.
    Vrhovac, V.
    Uprichard, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 462S - 462S
  • [2] Phase 2 trial of talabostat in stage IV melanoma.
    Redman, BG
    Ernstoff, MS
    Gajewski, TF
    Cunningham, C
    Lawson, DH
    Gregoire, L
    Haltom, E
    Uprichard, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 727S - 727S
  • [3] A phase 2 study of talabostat in patients with stage IV melanoma
    Gajewski, TF
    Lawson, DH
    Redman, BG
    Cunningham, C
    Agarwala, S
    Ernstoff, MS
    Haltom, EJ
    Gregoire, L
    Uprichard, MGJ
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 626 - 626
  • [4] Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
    Eager, Robert M.
    Cunningham, C. Casey
    Senzer, Neil N.
    Stephenson, Joe, Jr.
    Anthony, Stephen P.
    O'Day, Steven J.
    Frenette, Gary
    Pavlick, Anna C.
    Jones, Barry
    Uprichard, Margaret
    Nemunaitis, John
    BMC CANCER, 2009, 9
  • [5] Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
    Robert M Eager
    C Casey Cunningham
    Neil N Senzer
    Joe Stephenson
    Stephen P Anthony
    Steven J O'Day
    Gary Frenette
    Anna C Pavlick
    Barry Jones
    Margaret Uprichard
    John Nemunaitis
    BMC Cancer, 9
  • [6] Phase 2 study of talabostat/gemcitabine in Stage IV pancreatic cancer
    Nugent, F. W.
    Cunningham, C.
    Barve, M. A.
    Fisher, W.
    Patel, H.
    Meiri, E.
    Oza, Y. V.
    Yang, Z.
    Jurkowski, E. C.
    Uprichard, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Variates of survival for stage IV uveal melanoma.
    Rietschel, P
    Panageas, K
    Hanlon, C
    Patel, A
    Chapman, PB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 719S - 719S
  • [8] Temozolomide (TMZ) and cisplatin (CDDP) combination in naive patients with stage IV melanoma. Definitive results of a phase II multicenter trial
    Tourani, J.
    Wiersbicka, E.
    Mourey, L.
    Guillot, B.
    Sassolas, B.
    Bedane, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Phase 2 trial of talabostat and docetaxel in patients with stage IIIb/IV NSCLC.
    Cunningham, C
    Richards, D
    Salgia, R
    Leonard, R
    Raju, R
    Arseneau, J
    Packer, S
    Gregoire, L
    Haltom, L
    Uprichard, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 650S - 650S
  • [10] Cisplatin, interleukin-2, interferon-α and tamoxifen in metastatic melanoma.: A phase II study
    Naglieri, E
    Procacci, A
    Galetta, D
    Abbate, I
    Dell'Erba, L
    Colucci, G
    JOURNAL OF CHEMOTHERAPY, 1999, 11 (02) : 150 - 155
12345